Virtu KCG Holdings LLC Reduces Stake in GW Pharmaceuticals PLC (GWPH)
Virtu KCG Holdings LLC decreased its stake in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) by 11.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,471 shares of the biopharmaceutical company’s stock after selling 440 shares during the quarter. Virtu KCG Holdings LLC’s holdings in GW Pharmaceuticals PLC were worth $348,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Advisor Group Inc. increased its holdings in shares of GW Pharmaceuticals PLC by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the period. BNP Paribas Arbitrage SA bought a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth about $163,000. Woodmont Investment Counsel LLC bought a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth about $201,000. Quantitative Systematic Strategies LLC bought a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth about $204,000. Finally, Blair William & Co. IL bought a new position in shares of GW Pharmaceuticals PLC during the 1st quarter worth about $207,000. Institutional investors own 75.06% of the company’s stock.
Several research analysts have recently issued reports on GWPH shares. Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. ValuEngine upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Evercore ISI started coverage on shares of GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price objective on the stock. Finally, Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $143.05.
Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) opened at 111.25 on Tuesday. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $136.95. The stock’s 50 day moving average is $107.97 and its 200 day moving average is $107.72. The firm’s market capitalization is $2.82 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. During the same period in the prior year, the business posted ($0.05) earnings per share. Equities research analysts forecast that GW Pharmaceuticals PLC will post ($6.16) earnings per share for the current fiscal year.
GW Pharmaceuticals PLC Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.